Stay updated with breaking news from Thomas Copmann. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
For decades, the drug industry has yelled bloody murder each time Congress considered a regulatory measure that threatened its profits. But the hyperbole reached a new pitch in recent weeks as the Senate moved to adopt modest drug pricing negotiation measures in the Inflation Reduction Act.
For decades, the drug industry has yelled bloody murder each time Congress considered a regulatory measure that threatened its profits. But the hyperbole reached a new pitch in recent weeks as the Senate moved to adopt modest drug pricing negotiation measures in the Inflation Reduction Act.
For decades, the drug industry has yelled bloody murder each time Congress considered a regulatory measure that threatened its profits. But the hyperbole reached a new pitch in recent weeks as the Senate moved to adopt modest drug pricing negotiation measures in the Inflation Reduction Act.
For decades, the drug industry has yelled bloody murder each time Congress considered a regulatory measure that threatened its profits.
As the Senate moved to adopt modest drug pricing negotiation measures, pharmaceutical companies made specious arguments.